JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer auf "Neutral" mit einem Kursziel von 30 US-Dollar belassen. Umsatz und Gewinn (EPS) des Pharmakonzerns dürften etwas... ► Artikel lesen |
Wie BioNTech, Pfizer und Co? Hammer-Gerüchte um Astrazeneca | Der britisch-schwedische Pharma-Konzern Astrazeneca zählt zu den führenden Anbietern von Krebsmedikamenten. Zum Portfolio gehört unter anderem der Blockbuster Tagrisso, der zur Behandlung von Lungenkrebs... ► Artikel lesen |
XtalPi, Pfizer Expand AI-Powered Drug Discovery Collaboration With New Modeling Platform | NEW YORK CITY (dpa-AFX) - XtalPi (2228.HK) announced an expanded research collaboration with Pfizer (PFE) to develop a next-generation molecular modeling platform for drug discovery. The initiative... ► Artikel lesen |
Oscar Health Announces Fourth Quarter and Full Year 2024 Results; Introduces Full Year 2025 Outlook | NEW YORK--(BUSINESS WIRE)--Oscar Health, Inc. ("Oscar" or the "Company") (NYSE: OSCR), a leading healthcare technology company, today announced its financial results for the fourth quarter and... ► Artikel lesen |
Innoviz Technologies: Innoviz Regains Compliance with Nasdaq's Minimum Bid Price Requirement | TEL AVIV, Israel, July 3, 2025 /PRNewswire/ -- Innoviz Technologies Ltd. (NASDAQ: INVZ), (the "Company" or "Innoviz"), a leading Tier-1 direct supplier of high... ► Artikel lesen |
Innoviz Technologies: Innoviz Reports First Quarter 2025 Results | Record revenues and gross margins showcase the Company's progress toward achieving full-year targets and long-term goals
Accelerating LiDAR shipments to Volkswagen... ► Artikel lesen |
Innoviz Technologies: Innoviz Reports Fourth Quarter and Full Year 2024 Results | Recent financial and business developments leave Innoviz well-prepared for multiple program SOPs in 2026 and volume production of LiDARs in 2027
Partnership announcements... ► Artikel lesen |